A review of the metabolic effects of controlled-release Phentermine/Topiramate

Hormones

Volumn 12, Issue 4, 2013, Pages 507-516

  Kiortsis, Dimitrios N ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Anti obesity drugs; Metabolic parameters; Obesity; Phentermine; Topiramate; Weight loss

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; BETA 2 ADRENERGIC RECEPTOR; BICARBONATE; CARBONATE DEHYDRATASE V; CORTICOTROPIN RELEASING FACTOR; DECONGESTIVE AGENT; GALANIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LIPOPROTEIN LIPASE; LORCASERIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOAMINE OXIDASE INHIBITOR; NEUROPEPTIDE Y; NORADRENALIN; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRIACYLGLYCEROL;

ANOREXIA; ANTIOBESITY ACTIVITY; ANXIETY DISORDER; ATTENTION DISTURBANCE; BICARBONATE BLOOD LEVEL; BINGE EATING DISORDER; BIRTH INJURY; BLURRED VISION; BODY MASS; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; CLOSED ANGLE GLAUCOMA; COMORBIDITY; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DIZZINESS; DRUG ACTIVITY; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; DYSGEUSIA; ELEVATED BLOOD PRESSURE; ENERGY EXPENDITURE; ENZYME ACTIVITY; EVIDENCE BASED MEDICINE; EXERCISE; EYE DISCOMFORT; FATIGUE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSOMNIA; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIPOGENESIS; LOW CALORY DIET; LOW DRUG DOSE; MACROSOMIA; MEMORY DISORDER; METABOLIC ACIDOSIS; METABOLIC SYNDROME X; MIGRAINE; MONOTHERAPY; MOOD DISORDER; MYOPIA; NEPHROLITHIASIS; NERVOUSNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORADRENALIN RELEASE; OBESITY; OFF LABEL DRUG USE; OLIGOHIDROSIS; PARESTHESIA; PHOTOPHOBIA; PROPHYLAXIS; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SCLERA DISEASE; SCLERA REDNESS; SEIZURE; SOMNOLENCE; SPONTANEOUS ABORTION; SUICIDAL IDEATION; SWEAT GLAND DISEASE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TERATOGENICITY; THERMOGENESIS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; XEROSTOMIA;

ANTI-OBESITY AGENTS; DELAYED-ACTION PREPARATIONS; DIET, REDUCING; DRUG THERAPY, COMBINATION; EXERCISE; FRUCTOSE; HUMANS; LIFE STYLE; OBESITY; PHENTERMINE; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84891516321     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1438     Document Type: Review

References (40)

1. Flegal KM, Carroll MD, Ogden CK, Johnson CL, 2002 Prevalence and trends in obesity among uS adults, 1999-2000. J am Med assoc 288: 1723-1727.
2. Klein S, Burke LE, Bray GA, et al, 2004 Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the american Heart association Council on Nutrition, Physical activity, and Metabolism: endorsed by the american College of Cardiology Foundation. Circulation 110: 2952-2967.
3. Poirier P, giles TD, Bray GA, et al, 2006 Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 american Heart association Scientific Statement on obesity and Heart Disease from the obesity Committee of the Council on Nutrition, Physical activity, and Metabolism. Circulation 113: 898-918.
4. Heal DJ, gosden J, Smith SL, 2009 Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br J Clin Pharmacol 68: 861-874.
5. Pi-Sunyer FX, 2004 The epidemiology of central fat distribution in relation to disease. Nutr rev 62: 120-126.
6. Kiortsis DN, Filippatos TD, Elisaf MS, 2005 The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabet Metab 31: 15-22.
7. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS, 2005 A review of the metabolic effects of sibutramine. Curr Med res op 21: 457-466.
8. Christopoulou FD, Kiortsis DN, 2011 An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther 36: 10-18.
9. Kang JG, Park CY, 2012 Anti-obesity Drugs: a review about Their effects and Safety. Diabetes Metab J 36: 13-25.
10. Klonoff DC, Greenway F, 2008 Drugs in the pipeline for the obesity market. J Diabetes Sci Technol 2: 913-918.
11. Bays H, 2010 Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. Expert rev Cardiovasc Ther 8: 1777-1801.
12. Li Z, Maglione M, Tu W, et al, 2005 Meta-analysis: pharmacologic treatment of obesity. Ann intern Med 142:532-546.
13. Glazer G, 2001 Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch intern Med 161: 1814-1824.
14. Ioannides-Demos LL, Piccenna L, McNeil JJ, 2011 Pharmacotherapies for obesity: past, current, and future therapies. J obes 2011: 179674.
15. Witkamp RF, 2011 Current and future drug targets in weight management. Pharm res 28: 1792-1818.
16. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M, 2002 Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J obes relat Metab Disord 26: 262-273.
17. Shekelle PG, Morton SC, Maglione M, et al, 2004 Pharmacological and surgical treatment of obesity. Evid rep Technol assess 103: 1-6.
18. Kennett GA, Clifton PG, 2010 New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Pharmacol Biochem Behav 97: 63-83.
19. Khazaal Y, Zullino DF, 2007 Topiramate-induced weight loss is possibly due to the blockade of conditioned and automatic processes. Eur J Clin Pharmacol, 63: 891-892.
20. Mcelroy SL, arnold LM, Shapira NA, et al, 2003 Topira-mate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlledtrial. Am J Psychiatry 160: 255-261.
21. Khazaal Y, Zullino DF, 2006 Topiramate in the treatment of compulsive sexual behavior: case report. BMC Psychiatry 6: 22.
22. Turenius CI, Htut MM, Prodon DA, et al, 2009 Gaba(a) receptors in the lateral hypothalamus as mediators of satiety and body weight regulation. Brain res 1262: 16-24.
23. Erondu N, Gantz I, Musser B, et al, 2006 Neuropep-tide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 4: 275-282.
24. Husum H, Van Kammen D, Termeer E, Bolwig G, Mathé A, 2003 Topiramate normalizes hippocampal NPY-Li in flinders sensitive line 'depressed' rats and upregulates NPY, galanin, and CrH-Li in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects. Neuropsychopharmacology 28: 1292-1299.
25. Schütt M, Brinkhoff J, Drenckhan M, Lehnert H, Som-mer C, 2010 Weight reducing and metabolic effects of topiramate in patients with migraine--an observational study. Exp Clin endocrinol Diabetes 118: 449-452.
26. Theisen FM, Beyenburg S, Gebhardt S, et al, 2008 A prospective study of body weight and serum leptin levels in patients treated with topiramate. Clin Neuropharmacol 31: 226-230.
27. Tremblay A, Chaput JP, Bérubé-Parent S, et al, 2007 The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension. Eur J Clin Pharmacol 63: 123-134.
28. Winum JY, Scozzafava A, Montero JL, Supuran CT, 2005 Sulfamates and their therapeutic potential. Med res rev 25: 186-228.
29. Poulsen SA, Wilkinson BL, Innocenti A, Vullo D, Supuran CT, 2008 Inhibition of human mitochondrial carbonic anhydrases Va and VB with para-(4-phenyltriazole-1-yl)-benzenesulfonamide derivatives. Bioorg Med Chem Lett 18: 4624-4627.
30. Vullo D, Franchi M, Gallori E, Antel J, Scozzafava A, Supuran CT, 2004 Carbonic anhydrase inhibitors. inhibition of mitochondrial isozyme V with aromatic and heterocyclicsulfonamides. J Med Chem 47: 1272-1279.
31. Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y, 2000 Influence of topiramate in the regulation of energy balance. Nutrition 16: 961-966.
32. Gadde KM, Allison DB, Ryan DH, et al, 2011 Effects of low dose, controlled release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CoNQuer): a randomised, placebo-controlled, phase 3 trial. Lancet 377: 1341-1352.
33. Garvey WT, Ryan DH, Look M, et al, 2012 Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SeQueL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 95: 297-308.
34. Allison DB, Gadde KM, Garvey WT, et al, 2012 Con-trolled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (eQuiP). Obesity (Silver Spring) 20: 330-342.
35. Garvey WT, Ryan DH, Henry R, et al, 2013 Prevention of type 2 Diabetes in subjects with prediabetes and meta-bolic syndrome treated with phentermine and topiramate extended release. Diabetes Care [epub ahead of print]
36. Margulis AV, Mitchell AA, Gilboa SM, et al, 2012 Use of topiramate in pregnancy and risk of oral clefts. Am J obstet gynecol 207: 405e1-7.
37. Green MW, Seeger JD, Peterson C, Bhattacharyya A, 2012 Utilization of topiramate during pregnancy and risk of birth defects. Headache 52: 1070-1084.
38. Hunt S, Russell A, Smithson WH, et al, 2008 Topiramate in pregnancy: preliminary experience from the uK epilepsy and Pregnancy register. Neurology 71: 272-276.
39. Malgarini RB, Pimpinella G, 2011 Phentermine plus topiramate in the treatment of obesity. Lancet 378: 125-126.
40. Heal DJ, Gosden J, Smith SL, 2012 What is the prognosis for new centrally-acting anti-obesity drugs? Neurophar-macology 63: 132-146.